Last reviewed · How we verify

Avastin in combination with Roferon-A

Central European Society for Anticancer Drug Research · Phase 2 active Small molecule

Avastin in combination with Roferon-A is a Antiangiogenic agent and Immunomodulator Small molecule drug developed by Central European Society for Anticancer Drug Research. It is currently in Phase 2 development for Metastatic colorectal cancer, Non-small cell lung cancer. Also known as: Bevacizumab in combination with Interfereon-alfa.

Avastin (bevacizumab) inhibits angiogenesis by binding to vascular endothelial growth factor (VEGF), while Roferon-A (interferon alfa-2a) modulates the immune response and has antiproliferative effects.

Avastin (bevacizumab) inhibits angiogenesis by binding to vascular endothelial growth factor (VEGF), while Roferon-A (interferon alfa-2a) modulates the immune response and has antiproliferative effects. Used for Metastatic colorectal cancer, Non-small cell lung cancer.

At a glance

Generic nameAvastin in combination with Roferon-A
Also known asBevacizumab in combination with Interfereon-alfa
SponsorCentral European Society for Anticancer Drug Research
Drug classAntiangiogenic agent and Immunomodulator
TargetVEGF
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

Avastin works by binding to VEGF, preventing its interaction with its receptor and thus inhibiting the formation of new blood vessels that tumors need to grow. Roferon-A, on the other hand, stimulates the immune system to recognize and attack cancer cells, and also has direct antiproliferative effects on tumor cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Avastin in combination with Roferon-A

What is Avastin in combination with Roferon-A?

Avastin in combination with Roferon-A is a Antiangiogenic agent and Immunomodulator drug developed by Central European Society for Anticancer Drug Research, indicated for Metastatic colorectal cancer, Non-small cell lung cancer.

How does Avastin in combination with Roferon-A work?

Avastin (bevacizumab) inhibits angiogenesis by binding to vascular endothelial growth factor (VEGF), while Roferon-A (interferon alfa-2a) modulates the immune response and has antiproliferative effects.

What is Avastin in combination with Roferon-A used for?

Avastin in combination with Roferon-A is indicated for Metastatic colorectal cancer, Non-small cell lung cancer.

Who makes Avastin in combination with Roferon-A?

Avastin in combination with Roferon-A is developed by Central European Society for Anticancer Drug Research (see full Central European Society for Anticancer Drug Research pipeline at /company/central-european-society-for-anticancer-drug-research).

Is Avastin in combination with Roferon-A also known as anything else?

Avastin in combination with Roferon-A is also known as Bevacizumab in combination with Interfereon-alfa.

What drug class is Avastin in combination with Roferon-A in?

Avastin in combination with Roferon-A belongs to the Antiangiogenic agent and Immunomodulator class. See all Antiangiogenic agent and Immunomodulator drugs at /class/antiangiogenic-agent-and-immunomodulator.

What development phase is Avastin in combination with Roferon-A in?

Avastin in combination with Roferon-A is in Phase 2.

What are the side effects of Avastin in combination with Roferon-A?

Common side effects of Avastin in combination with Roferon-A include Hypertension, Fatigue, Headache.

What does Avastin in combination with Roferon-A target?

Avastin in combination with Roferon-A targets VEGF and is a Antiangiogenic agent and Immunomodulator.

Related